Identification
NameMelphalan
Accession NumberDB01042  (APRD00118)
TypeSmall Molecule
GroupsApproved
Description

An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen. [PubChem]

Structure
Thumb
Synonyms
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysine
Melfalano
Melphalanum
p-Bis(beta-chloroethyl)aminophenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
External IDs CB 3025 / CB-3025 / NCI-C04853 / NSC-241286 / NSC-8806 / SK 15673 / SK-15673
Product Ingredients
IngredientUNIICASInChI KeyDetails
Melphalan hydrochloride1VXP4V453T 3223-07-2OUUYBRCCFUEMLH-YDALLXLXSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlkeranKitApopharma Inc2011-01-01Not applicableUs
AlkeranTablet2 mgOralAspen Pharmacare Canada Inc.1964-12-31Not applicableCanada
AlkeranTablet, film coated2 mg/1OralApopharma Inc2011-01-01Not applicableUs
EvomelaInjection, powder, lyophilized, for solution50 mg/10mLIntravenousSpectrum Pharmaceuticals, Inc.2016-03-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MelphalanTablet2 mg/1OralAlvogen, Inc.2017-03-22Not applicableUs
Melphalan HydrochlorideKitGenera Medix Inc.2009-10-27Not applicableUs
Melphalan HydrochlorideKitMylan Institutional2014-09-29Not applicableUs
Melphalan HydrochlorideKitIntravenousActavis Pharma Company2017-01-13Not applicableUs
Melphalan HydrochlorideKitMylan Institutional2013-01-10Not applicableUs
Melphalan HydrochlorideKitIntravenousSagent Pharmaceuticals2016-09-09Not applicableUs
Melphalan HydrochlorideKitMylan Institutional2013-01-10Not applicableUs
Melphalan HydrochlorideInjection, powder, lyophilized, for solution50 mg/10mLIntravenousPar Pharmaceutical2016-08-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AlkeranAspen Pharmacare Canada Inc.
Categories
UNIIQ41OR9510P
CAS number148-82-3
WeightAverage: 305.2
Monoisotopic: 304.074533244
Chemical FormulaC13H18Cl2N2O2
InChI KeySGDBTWWWUNNDEQ-LBPRGKRZSA-N
InChI
InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
IUPAC Name
(2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid
SMILES
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Pharmacology
Indication

For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.

Structured Indications
Pharmacodynamics

Melphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
Absorption

Incomplete, variable, 25-89% post oral dose

Volume of distribution
  • 0.5 L/kg
Protein binding

Moderate to high (60 to 90%), primarily to albumin and, to a lesser extent, alpha 1-acid glycoprotein. 30% is irreversibly bound.

Metabolism

Melphalan is not actively metabolised, it spontaneously degrades to mono and dihydroxy products.

Route of elimination

The 24-hour urinary excretion of parent drug in these patients was 10% ± 4.5%, suggesting that renal clearance is not a major route of elimination of parent drug.

Half life

1.5 (±0.83) hours

ClearanceNot Available
Toxicity

Vomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract; The principal toxic effect is bone marrow suppression. LD50=11.2 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Melphalan.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Melphalan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.Approved
CarmustineThe risk or severity of adverse effects can be increased when Melphalan is combined with Carmustine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Melphalan is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Melphalan.Approved, Investigational
CyclosporineMelphalan may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Melphalan.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Melphalan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Melphalan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.Approved, Investigational
FingolimodMelphalan may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Melphalan is combined with G17DT.Investigational
INGN 201The risk or severity of adverse effects can be increased when Melphalan is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Melphalan is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Melphalan is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Melphalan.Withdrawn
Nalidixic AcidThe risk or severity of adverse effects can be increased when Nalidixic Acid is combined with Melphalan.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Melphalan.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Melphalan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Melphalan is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Melphalan.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.Approved
SRP 299The risk or severity of adverse effects can be increased when Melphalan is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Melphalan.Approved, Investigational
TofacitinibMelphalan may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Melphalan.Approved, Investigational
Food Interactions
  • Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake.
References
Synthesis ReferenceUS3032584
General References
  1. Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. doi: 10.1021/tx7004508. Epub 2008 Feb 14. [PubMed:18324787 ]
  2. Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15. [PubMed:16781199 ]
  3. Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7. [PubMed:8398701 ]
External Links
ATC CodesL01AA03 — Melphalan
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (175 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1Active Not RecruitingTreatmentLymphoma, B-Cell / Malignant Lymphomas1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedSupportive CareMucositis / Multiple Myeloma (MM)1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndrome1
1CompletedTreatmentAllogeneic Stem Cell Transplantation / Malignancies, Hematologic1
1CompletedTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas / Transplantation Infection / Transplantation, Bone Marrow1
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Leukemias / Malignant Lymphomas1
1CompletedTreatmentCancer, Ovarian2
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentCongenital Marrow Failures / Haemoglobinopathies congenital / Immunodeficiencies / Inborn Errors of Metabolism / Lysosomal Storage Diseases / Non Malignant Disorders / Sickle Cell / Thalassaemic disorders1
1CompletedTreatmentEwings Sarcoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1CompletedTreatmentLiver Cancer / Metastatic Cancers1
1CompletedTreatmentMalignancies, Hematologic1
1CompletedTreatmentMalignant Lymphomas4
1CompletedTreatmentMelanoma (Skin)1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Hepatic1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Hepatic1
1CompletedTreatmentNeuroblastomas4
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentSarcomas1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentWiskott-Aldrich Syndrome (WAS)1
1Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingBasic ScienceHematopoietic Stem Cell Transplantation (HSCT)1
1RecruitingTreatmentAdult Burkitt Lymphoma / Adult Diffuse Large B-Cell Lymphoma / CD20-Positive Neoplastic Cells Present / Indolent Adult Non-Hodgkin Lymphoma / Mantle Cell Lymphoma (MCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Refractory Mature B-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Hematological Diseases / Immune Deficiencies / Malignant Lymphomas / Multiple Myeloma (MM) / Tumors, Solid1
1RecruitingTreatmentAplastic Anaemia (AA) / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukaemia, Acute / Malignant Lymphomas / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentClear Cell Carcinoma / Ewing's Sarcoma (ES) / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Malignant Lymphomas / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Adenocarcinoma / Rhabdoid Tumors / Rhabdomyosarcomas / Wilms' tumor1
1RecruitingTreatmentDisseminated Sclerosis1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1RecruitingTreatmentHigh-risk Tumor / Malignant Lymphomas / Neuroblastomas1
1RecruitingTreatmentLeukemia, Plasma Cell / Recurrent Plasma Cell Myeloma1
1RecruitingTreatmentLeukemias1
1RecruitingTreatmentMature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentMetastases to spine / Spinal Diseases / Spinal Tumors1
1RecruitingTreatmentMultiple Myeloma (MM)2
1RecruitingTreatmentMultiple Myeloma, Refractory to Standard Treatment / Multiple Myeloma, Relapsed1
1RecruitingTreatmentPlasma Cell Myeloma1
1RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Hematologic Malignancy1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1SuspendedOtherDiffuse Intrinsic Pontine Glioma (DIPG)1
1TerminatedSupportive CareBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Chordomas / Liver Cancer / Neuroblastomas / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Liver Cancer / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers1
1TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1TerminatedTreatmentDrug/Agent Toxicity by Tissue/Organ / Multiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas / Myelodysplastic Syndrome / Myeloproliferative Disorders / Plasma Cell Myeloma1
1TerminatedTreatmentPlasma Cell Myeloma1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnSupportive CareAcute myeloid leukaemia (in remission) / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Acute Myeloid Leukemia / Secondary Myelofibrosis1
1WithdrawnTreatmentEwing's Sarcoma (ES)1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas / Pediatric Disorders / Transplantation, Stem Cell1
1WithdrawnTreatmentMelanoma (Skin)1
1WithdrawnTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAdvanced Hematologic Malignancies / Leukemias / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentInfection NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)5
1, 2CompletedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Transplantation, Stem Cell1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
1, 2CompletedTreatmentNeoplasms1
1, 2CompletedTreatmentPlasma Cell Myeloma2
1, 2CompletedTreatmentPlasma Cell Myeloma / Transplantation, Stem Cell1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Oligoastrocytoma / Recurrent Adult Brain Neoplasm1
1, 2RecruitingTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Adult Ependymoblastoma / Adult Medulloblastoma / Adult Pineoblastoma / Adult Supratentorial Embryonal Tumor, Not Otherwise Specified / Adult Supratentorial Primitive Neuroectodermal Tumor / Atypical Teratoid/Rhabdoid Tumor / Central Nervous System Embryonal Tumor / Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Childhood Ependymoblastoma / Germ Cell Tumors / Medulloepithelioma / Ototoxicity / Recurrent Adult Brain Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
1, 2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma / Refractory T-Cell Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentBeta Thalassemia-Major / Sickle Cell Disorders1
1, 2RecruitingTreatmentFollicular Lymphoma (FL) / Hodgkin's Lymphoma - Relapsed/Refractory / Non-Hodgkin's Lymphoma - Aggressive1
1, 2RecruitingTreatmentHaemoglobinopathies congenital / Hematologic, Immune, or Bone Marrow Disorders / Metabolic Disorders / Non-malignant Disorders1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Plasmablastic Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Follicular Lymphoma / Stage III Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Diseases1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMultiple Myeloma (MM)3
1, 2RecruitingTreatmentMultiple Myeloma in Relapse1
1, 2RecruitingTreatmentPlasma Cell Leukemia in Remission / Plasma Cell Myeloma1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2TerminatedTreatmentAnemias / Immunodeficiencies / Leukemias / Malignant Lymphomas / Neuroblastomas1
1, 2TerminatedTreatmentCancers / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentChronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy / Leukaemia, Acute / Lymphoma, Hodgkins / Malignancies, Hematologic / Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
1, 2TerminatedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentLeukemias / Myeloproliferative Diseases / Plasma Cell Myeloma1
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2Unknown StatusTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Unknown StatusTreatmentBlood And Marrow Transplantation / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Transplantation Infection1
1, 2Unknown StatusTreatmentCancer, Breast1
1, 2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2WithdrawnTreatmentMalignant Lymphomas1
1, 2WithdrawnTreatmentMelanoma1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)1
2Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAmyloidosis1
2Active Not RecruitingTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentDiffuse Large Cell Lymphoma / Malignant Lymphomas1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentHIV Disease / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentHemoglobinuria, Paroxysmal Nocturnal (PNH) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia, Acute Lymphocytic (ALL) / Leukemia, Myeloid, Acute(AML) / Leukemia, Myeloid, Chronic(CML) / Lymphoma, Hodgkins / Lymphoma, Non-Hodgkin (NHL) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentHigh Risk Neuroblastoma1
2Active Not RecruitingTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentJuvenile Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentMalignant Lymphomas4
2Active Not RecruitingTreatmentMultiple Myeloma (MM)7
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurotoxicity1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2CompletedNot AvailableMultiple Myeloma (MM)1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Histiocytosis / Myelodysplasia1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukemia, Lymphocytic / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2CompletedTreatmentAdrenoleukodystrophy / Gangliosidosis, GM1 / I-Cell Disease / Leukodystrophy, Globoid Cell / Metachromatic Leukodystrophy / Sandhoffs Disease / Sanfilippo Syndrome / Tay Sachs Disease / Wolman's Disease1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / Multiple Myeloma (MM) / Neoplasms, Hematologic / Paroxysmal Hemoglobinuria1
2CompletedTreatmentAllogeneic Marrow Transplant / Leukemias / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAngiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2CompletedTreatmentBlood Cancers / Multiple Myeloma (MM)1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancers1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentColorectal Cancers / Islet Cell Tumor / Liver Cancer / Metastatic Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers2
2CompletedTreatmentDisseminated Sclerosis / Relapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEwings Sarcoma / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
2CompletedTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias2
2CompletedTreatmentLeukemias / Malignant Lymphomas3
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentLymphoma, Large Cell, Diffuse1
2CompletedTreatmentMalignant Lymphomas13
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma (MM)1
2CompletedTreatmentMalignant Lymphomas / Transplantation, Bone Marrow1
2CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMalignant Neoplasm of Prostate1
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMelanoma (Skin) / Sarcomas1
2CompletedTreatmentMultiple Myeloma (MM)11
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentLight chain amyloidosis / Multiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm15
2CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2CompletedTreatmentNeuroblastomas4
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage IIB Adult Soft Tissue Sarcoma / Stage IIC Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IVA Adult Soft Tissue Sarcoma / Stage IVB Adult Soft Tissue Sarcoma1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRefractory Plasma Cell Neoplasm / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentSarcomas3
2Enrolling by InvitationTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentAmyloidosis; Systemic1
2Not Yet RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentCancer, Appendiceal / Colorectal Cancers1
2Not Yet RecruitingTreatmentHematological Malignancy Undergoing a Related Donor Haploidentical HCT / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)4
2Not Yet RecruitingTreatmentMultiple Myeloma in Relapse1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / CMML / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Hematopoietic Stem Cell Transplant (HSCT) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia in Remission / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome1
2RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
2RecruitingTreatmentAutoimmune Diseases / Autoimmune Disorders1
2RecruitingTreatmentAutoimmune Lymphoproliferative Syndrome / Bruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immune Deficiency (CVID) / DiGeorge's syndrome / Hyper-IgM / Immune Deficiency Disorders / Immune Dysregulatory Disorder / Immune Dysregulatory Disorders / IPEX / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Syndrome1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentBeta Thalassemia / Bone Marrow Failure / Histiocytosis / Immunodeficiencies / Inborn Errors of Metabolism / Leukemias / Malignant Lymphomas / Sickle Cell Disorders1
2RecruitingTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / De Novo Myelodysplastic Syndrome / Leukemias / Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentChildren / Retinal Neoplasms / Retinoblastoma1
2RecruitingTreatmentCongenital Bone Marrow Failure Syndromes / Hereditary Anemias / Inherited Metabolic Disorders (IMD) / Patients With Sickle Disease Presenting Specific Symptoms / Primary Immunodeficiency Syndromes1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentExtranodal NK-T-CELL LYMPHOMA / NK/T Cell Lymphoma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentHaematological Malignancies1
2RecruitingTreatmentHepatocellular,Carcinoma / Intrahepatic Cholangiocarcinoma1
2RecruitingTreatmentIntracranial Non-germinomatous Germ Cell Tumor1
2RecruitingTreatmentLeukemia, Erythroblastic, Acute / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemias / Malignant Lymphomas1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Diseases / Plasma Cell Myeloma1
2RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL)1
2RecruitingTreatmentMalignant Neoplasm of Prostate1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentMultiple Myeloma (MM)8
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentPlasma Cell Myeloma2
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentRefractory and/or Relapsed Metastatic Solid Tumors1
2RecruitingTreatmentSickle Cell Disorders1
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2RecruitingTreatmentTesticular Cancer1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2TerminatedDiagnosticMalignant Lymphomas1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Breast / Cancer, Ovarian1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia, Lymphoblastic, Acute / Leukemia, Myeloid, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentHematological Diseases1
2TerminatedTreatmentHistiocytosis, Langerhans-Cell1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Diseases / Plasma Cell Myeloma1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Other Haematological Diseases1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMultiple Myeloma (MM)4
2TerminatedTreatmentMultiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Plasma Cell Neoplasms1
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentPlasma Cell Myeloma1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentRetinoblastoma2
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML)1
2Unknown StatusTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2Unknown StatusTreatmentChildhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas5
2Unknown StatusTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentMedulloblastomas / Neoplasms, Brain / Neuroectodermal Tumors, Primitive1
2Unknown StatusTreatmentMultiple Myeloma (MM)2
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2Unknown StatusTreatmentNeoplasms, Brain1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentNon Hodgkin Lymphoma (NHL)1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)2
2Unknown StatusTreatmentRenal Cancers1
2Unknown StatusTreatmentSarcoma of Pelvis1
2Unknown StatusTreatmentSevere Thalassemia1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentMalignant Lymphomas2
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2, 3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3Not Yet RecruitingTreatmentBile Duct Carcinoma / Intrahepatic Cholangiocarcinoma1
2, 3RecruitingTreatmentCastrate Resistant Prostate Cancer (CRPC)1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3RecruitingTreatmentMultiple Myeloma (MM)1
2, 3TerminatedTreatmentAML / Leukemia, Lymphocytic, Acute / Smith-Magenis Syndrome1
2, 3TerminatedTreatmentNeuroblastomas1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)5
3Active Not RecruitingTreatmentMultiple Myeloma (MM) / Newly Diagnosed Patients1
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentAL Amyloidosis1
3CompletedTreatmentAcute Myeloid Leukaemias (AML)1
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentCancer, Ovarian1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentIntraocular Melanoma / Melanoma (Skin) / Metastatic Cancers1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMalignant Lymphomas4
3CompletedTreatmentMelanoma1
3CompletedTreatmentMultiple Myeloma (MM)11
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
3CompletedTreatmentMultiple Myeloma de Novo Treatment1
3CompletedTreatmentNeuroblastomas3
3CompletedTreatmentNewly Diagnosed Multiple Myeloma1
3CompletedTreatmentPrimary Systemic Amyloidosis (AL)1
3CompletedTreatmentRecurrent Melanoma / Stage III Melanoma1
3CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3No Longer AvailableNot AvailableMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentEwing's Sarcoma (ES)1
3RecruitingTreatmentMultiple Myeloma (MM)3
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSickle Cell Disorders1
3TerminatedTreatmentAL Amyloidosis1
3TerminatedTreatmentLeukemia, Myelocytic, Acute1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentMultiple Myeloma (MM)2
3TerminatedTreatmentNewly Diagnosed, Multiple Myeloma1
3TerminatedTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMalignant Lymphomas4
3Unknown StatusTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
3Unknown StatusTreatmentNeuroblastomas3
3Unknown StatusTreatmentSarcomas1
4CompletedNot AvailableMultiple Myeloma (MM)1
4RecruitingTreatmentMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Neuroblastoma / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Regional Neuroblastoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Rhabdomyosarcoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Soft Tissue Sarcoma / Ewing's Sarcoma (ES) / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Ovarian Mixed Germ Cell Tumor / Previously Untreated Childhood Rhabdomyosarcoma / Recurrent Adult Brain Tumor / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Extragonadal Germ Cell Tumor / Recurrent Extragonadal Non-seminomatous Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Neuroblastoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Tumors, Solid / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableActive Not RecruitingTreatmentChronic Leukemias / Leukaemia, Acute / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableActive Not RecruitingTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableActive Not RecruitingTreatmentUnilateral Retinoblastoma1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplasia1
Not AvailableCompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentAcute Myeloid Leukaemias (AML) / Agnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukaemia, Acute / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myeloproliferative Disorders / Polycythemia Vera (PV)1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentHodgkins Disease (HD)1
Not AvailableCompletedTreatmentLysosomal Storage Diseases / Peroxisomal Disorders1
Not AvailableCompletedTreatmentMalignant Lymphomas1
Not AvailableCompletedTreatmentMalignant Lymphomas / Neuroblastomas / Tumors, Central Nervous System / Wilms' tumor1
Not AvailableCompletedTreatmentRetinoblastoma1
Not AvailableNo Longer AvailableNot AvailableCutaneous Melanoma / Hepatic cancer metastatic / Ocular Melanoma1
Not AvailableRecruitingNot AvailableMetastatic Melanoma1
Not AvailableRecruitingSupportive CarePrimary Myelofibrosis / Secondary Myelofibrosis1
Not AvailableRecruitingTreatmentAdvanced Intra-Ocular Retinoblastoma / Retinoblastoma1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentHaplo-Cord Transplantation / Malignancies, Hematologic1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentMalignancies, Hematologic1
Not AvailableRecruitingTreatmentMyelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentLeukemias / Malignant Lymphomas1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMultiple Myeloma (MM)1
Not AvailableWithdrawnTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I AIDS-related Lymphoma / Stage II AIDS-related Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableWithdrawnTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableWithdrawnTreatmentBasal Cell Carcinoma of the Skin / Eccrine Carcinoma of the Skin / Recurrent Adult Soft Tissue Sarcoma / Recurrent Melanoma / Recurrent Skin Cancer / Squamous Cell Carcinoma of the Skin / Stage III Adult Soft Tissue Sarcoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Adult Soft Tissue Sarcoma / Stage IV Melanoma1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit; powder, for solution; solutionIntra-arterial; Intravenous
TabletOral2 mg
Tablet, film coatedOral2 mg/1
Injection, powder, lyophilized, for solutionIntravenous50 mg/10mL
TabletOral2 mg/1
Kit
KitIntravenous
Prices
Unit descriptionCostUnit
Alkeran 50 mg vial1971.72USD vial
Melphalan hcl 50 mg vial1845.6USD vial
Alkeran 2 mg tablet5.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341114 No2000-10-102017-10-10Canada
US8410077 No2009-03-132029-03-13Us
US9200088 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)182.5 °CPhysProp
water solubility< 0.1 g/100 mL at 22 °CNot Available
logP-0.52SANGSTER,J (1994) @pH=7.4
Predicted Properties
PropertyValueSource
Water Solubility0.358 mg/mLALOGPS
logP-0.22ALOGPS
logP0.25ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)1.29ChemAxon
pKa (Strongest Basic)9.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area66.56 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.23 m3·mol-1ChemAxon
Polarizability31.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9523
Blood Brain Barrier-0.6073
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.983
P-glycoprotein inhibitor IINon-inhibitor0.9192
Renal organic cation transporterNon-inhibitor0.811
CYP450 2C9 substrateNon-substrate0.8457
CYP450 2D6 substrateNon-substrate0.7432
CYP450 3A4 substrateNon-substrate0.7553
CYP450 1A2 substrateInhibitor0.779
CYP450 2C9 inhibitorNon-inhibitor0.9348
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9193
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9863
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.7873
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.9179 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8187
hERG inhibition (predictor II)Non-inhibitor0.8488
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-000w-2930000000-b95beb5e9c3e61b7687fView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPhenylalanine and derivatives
Alternative ParentsPhenylpropanoic acids / Amphetamines and derivatives / L-alpha-amino acids / Aniline and substituted anilines / Dialkylarylamines / Nitrogen mustard compounds / Aralkylamines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids
SubstituentsPhenylalanine or derivatives / 3-phenylpropanoic-acid / Alpha-amino acid / Amphetamine or derivatives / L-alpha-amino acid / Nitrogen mustard / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptorsorganochlorine compound, non-proteinogenic L-alpha-amino acid, L-phenylalanine derivative, nitrogen mustard (CHEBI:28876 )

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Monahan SD, Subbotin VM, Budker VG, Slattum PM, Neal ZC, Herweijer H, Wolff JA: Rapidly reversible hydrophobization: an approach to high first-pass drug extraction. Chem Biol. 2007 Sep;14(9):1065-77. [PubMed:17884638 ]
  4. Lee PC, Kakadiya R, Su TL, Lee TC: Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia. 2010 May;12(5):376-87. [PubMed:20454509 ]
  5. Wang F, Li F, Ganguly M, Marky LA, Gold B, Egli M, Stone MP: A bridging water anchors the tethered 5-(3-aminopropyl)-2'-deoxyuridine amine in the DNA major groove proximate to the N+2 C.G base pair: implications for formation of interstrand 5'-GNC-3' cross-links by nitrogen mustards. Biochemistry. 2008 Jul 8;47(27):7147-57. doi: 10.1021/bi800375m. Epub 2008 Jun 13. [PubMed:18549246 ]
  6. Vasquez KM: Targeting and processing of site-specific DNA interstrand crosslinks. Environ Mol Mutagen. 2010 Jul;51(6):527-39. doi: 10.1002/em.20557. [PubMed:20196133 ]
  7. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP: Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica. 2007 Nov;92(11):1505-12. [PubMed:18024399 ]
  8. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS: The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005 Jul 15;106(2):698-705. Epub 2005 Mar 31. [PubMed:15802532 ]
  9. Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15. [PubMed:16781199 ]
  10. Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. doi: 10.1021/tx7004508. Epub 2008 Feb 14. [PubMed:18324787 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peptide antigen binding
Specific Function:
Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the ...
Gene Name:
SLC7A5
Uniprot ID:
Q01650
Molecular Weight:
55009.62 Da
References
  1. Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7. [PubMed:8398701 ]
Drug created on June 13, 2005 07:24 / Updated on July 20, 2017 13:29